Ownership and insider activity for CG Oncology Inc. (CGON): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in...
Price
| Price | $74.12 |
| Market Cap | $6.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-14 | POST LEONARD E | M-Exempt | 1,000 | $600 |
| 2026-08-14 | POST LEONARD E | M-Exempt | 1,000 | $600 |
| 2026-08-14 | POST LEONARD E | S-Sale | 1,000 | $75K |
| 2026-07-15 | POST LEONARD E | M-Exempt | 1,000 | $600 |
| 2026-07-15 | POST LEONARD E | M-Exempt | 1,000 | $600 |
| 2026-07-15 | POST LEONARD E | S-Sale | 1,000 | $71K |
| 2026-07-10 | Mulay James | M-Exempt | 24,165 | $644K |
| 2026-07-10 | Mulay James | S-Sale | 24,165 | $1.8M |
| 2026-07-10 | Mulay James | M-Exempt | 24,165 | $644K |
| 2026-06-25 | Liu Brian Guan-Chyun | P-Purchase | 371,085 | $24.8M |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $53.6M | $88.1M | $8.3M | $257.1M | $32.5M |
| Short-term Investments | 0 | $55.3M | $179.4M | $484.9M | $709.7M |
| Receivables | $2000 | $303000 | $92000 | $781000 | $688000 |
| Inventory | 0 | 0 | 0 | 0 | $1.6M |
| Total Current Assets | $58.4M | $147.2M | $194.1M | $754.2M | $759.5M |
| Property, Plant & Equipment | $200000 | $506000 | $491000 | $493000 | $19.6M |
| Goodwill | 0 | 0 | 0 | 0 | $10.3M |
| Intangible Assets | 0 | 0 | 0 | 0 | $575000 |
| Total Assets | $58.7M | $147.7M | $199.3M | $754.8M | $791.6M |
| Accounts Payable | $1.0M | $985000 | $3.2M | $6.5M | $5.7M |
| Short-term Debt | $2.9M | $9.0M | $569000 | 0 | 0 |
| Total Current Liabilities | $6.0M | $15.4M | $14.3M | $21.4M | $30.8M |
| Long-term Debt | $12.1M | $6.5M | 0 | 0 | $3.0M |
| Total Liabilities | $18.4M | $22.6M | $14.5M | $21.4M | $39.0M |
| Retained Earnings | -$45.9M | -$81.3M | -$129.9M | -$218.0M | -$379.0M |
| Total Equity | $40.3M | $125.2M | $184.8M | $733.4M | $752.6M |
| Total Debt | $15.1M | $15.9M | $1.0M | $238000 | $7.0M |
| Net Debt | -$38.5M | -$127.5M | -$186.6M | -$741.8M | -$735.1M |
| Working Capital | $52.4M | $131.8M | $179.9M | $732.8M | $728.6M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 22.22 |
Profitability
| Return on Equity | -25.20% |
| Return on Invested Capital | -24.30% |
| Return on Assets | -20.67% |
| Gross Margin | -82.69% |
| Operating Margin | -4056.18% |
| Net Margin | -3602.68% |
Related companies: AAPG · APGE · CELC · CNTA · IRON · LEGN · RARE
Explore sector: Healthcare · Biotechnology
More sections of CGON: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks